SLC5A2 and chronic kidney disease: Last but not least, in the Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes-2022 [19], ADA preferably recommended SGLT-2 inhibitors and finerenone over GLP-1 RA in vulnerable population who were at increased risk for cardiovascular events or CKD progression.